Browsing Tag
TScan Therapeutics
2 posts
Does FDA clearance across three HLA subtypes de-risk TScan Therapeutics’ platform strategy?
FDA clears TSC-102-A01 and TSC-102-A03 for TScan Therapeutics. Explore how expanded HLA reach reshapes its heme cell therapy strategy.
March 2, 2026
TScan, Novartis to develop T cell receptor therapies for solid tumors
TScan Therapeutics has partnered with Swiss pharma giant Novartis to discover and develop novel TCR-engineered T cell receptor…
April 22, 2020